Literature DB >> 1607415

Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. Results of placebo-controlled, double-blind, multicenter trials.

B Berman1, C Ellis, J Leyden, N Lowe, R Savin, J Shupack, M Stiller, E Tschen, N Zaias, J E Birnbaum.   

Abstract

BACKGROUND: Patients with tinea pedis often discontinue treatment before eradication of the fungus when their symptoms improve. The result is an incomplete cure/recurrence.
OBJECTIVE: Terbinafine, a topical fungicidal agent, was evaluated in double-blind, placebo-controlled trials (159 patients) for its ability to achieve cure and relief of symptoms in the same time frame, that is, before compliance wanes.
METHODS: Mycologic characteristics (with potassium hydroxide examination and culture) and clinical signs and symptoms were assessed at baseline, at the end of a 1-week, twice-daily treatment and at 1, 3, and 5 weeks after the completion of therapy.
RESULTS: Both terbinafine and vehicle provided early relief of symptoms. However, only terbinafine gave progressive mycologic improvement such that at 5 weeks after treatment, 88% of the patients receiving terbinafine had converted from positive to negative mycology compared with 23% of the patients treated with vehicle.
CONCLUSION: The rapid and potent fungicidal action of terbinafine results in a high cure rate in interdigital tinea pedis with 1 week of treatment and may avoid failures caused by non-compliance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607415     DOI: 10.1016/0190-9622(92)70141-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  An overview of topical antifungal therapy in dermatomycoses. A North American perspective.

Authors:  A K Gupta; T R Einarson; R C Summerbell; N H Shear
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections.

Authors:  R Davis; J A Balfour
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

Review 3.  Pharmacoeconomic analysis of topical treatments for tinea infections.

Authors:  N H Shear; T R Einarson; S R Arikian; J J Doyle
Journal:  Pharmacoeconomics       Date:  1995-03       Impact factor: 4.981

Review 4.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 5.  [Topical terbinafine. Reduction of duration of therapy for tinea pedis].

Authors:  M-H Schmid-Wendtner; H Korting
Journal:  Hautarzt       Date:  2008-12       Impact factor: 0.751

Review 6.  Treatment and prophylaxis of tinea infections.

Authors:  G E Piérard; J E Arrese; C Piérard-Franchimont
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

7.  Comparison of terbinafine and clotrimazole in treating tinea pedis.

Authors:  E G Evans; B Dodman; D M Williamson; G J Brown; R G Bowen
Journal:  BMJ       Date:  1993-09-11

Review 8.  Topical treatments for fungal infections of the skin and nails of the foot.

Authors:  F Crawford; S Hollis
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.